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Rationale: Cough is the most frequent reason for consultation with
a familydoctor,or witha general or respiratory physician. Treatment
options are limited and one meta-analysis concluded that over-the-
counter remedies are ineffective. There is also increasing concern
about their use in children. Environmental irritants such as air
pollution and cigarette smoke are thought to evoke cough by
stimulating airway sensory nerves; however, how this occurs is not
fully understood.
Objectives: We hypothesized that the TRPA1 (transient receptor
potential cation channel, subfamily A, member 1) receptor may have
a role as a novel target for tussive agents given that many potential
irritants have been shown to activate this channel.
Methods: We investigated theeffect ofTRPA1 ligandsonvagal sensory
nerve activity in vitro and in guinea pig and human tussive challenge
models.
MeasurementsandMainResults: We demonstratedthat TRPA1 agonists
such as acrolein activate cloned human TRPA1 channels in HEK293
cells and also vagal sensory nerves in murine, guinea pig, and human
tissues. A role for TRPA1 was confirmed, using specific inhibitors and
tissue from Trpa12/2 gene–deleted animals. Finally, TRPA1 ligands
evokedreproducible tussive responses in botha guineapig model and
normal volunteers.
Conclusions: This study identifies the TRPA1 receptor as a promiscuous
receptor, activated by a wide range of stimuli, making it a perfect
target for triggering cough and as such one of the most promising
targets currently identified for the development of antitussive drugs.
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Cough is the most frequent reason for consultation with a family
doctor (1), or with a general or respiratory physician. Patients
with chronic cough probably account for 10–38% of respiratory
outpatient practice in the United States (2). Chronic cough, of
various etiologies, is a common presentation to specialist respi-
ratory clinics and is reported as a troublesome symptom by 7%
of the population (3). Treatment options are limited. A meta-
analysis concluded that over-the-counter cough remedies are
ineffective (4), and there is increasing concern about the use of
over-the-counter therapies in children. Despite its importance
our understanding of the mechanisms that provoke cough is poor.
Ion channels of the transient receptor potential (TRP) class
have been implicated in the afferent sensory loop of the cough
reflex (5–7) and in the heightened cough sensitivity seen in
disease (8). Agonists of the TRPV1 (transient receptor poten-
tial cation channel, subfamily V, member 1) capsaicin receptor,
such as vanilloids and protons, are among the most potent
chemical stimuli that cause cough (5–7). Another TRP receptor,
TRPA1 (transient receptor potential cation channel, subfamily
A, member 1), which is not activated by capsaicin, has been
shown to bind ligands such as acrolein, which is present in air
pollution and the acrid smoke from organic material (9). We
hypothesized that TRPA1 may have a role as a novel target for
tussive agents.
TRPA1 is a Ca21-permeant nonselective channel with 14
ankyrin repeats in its amino terminus, which belongs to the
larger TRP family (10). TRPA1 has been characterized as
a thermoreceptor that is activated by cold temperature (11).
In addition, TRPA1 channels are activated by a range of natural
products such as allyl isothiocyanate, allicin, and cannabinol,
found in mustard oil, garlic, and cannabis, respectively (12–14).
The channel is also activated by a multitude of environmental
irritants such as isothiocyanate, cinnamaldehyde, and acrolein.
The latter is present in air pollution, vehicle exhaust, and cig-
arette smoke (9, 15–20). TRPA1 is expressed primarily in small-
diameter, nociceptive neurons where its activation probably
contributes to the perception of noxious stimuli and the phe-
nomena known as inflammatory hyperalgesia and neurogenic
inflammation (9, 17, 19).
The respiratory tract is innervated by sensory afferent nerves
including the myelinated, rapidly adapting receptors and the
nonmyelinated, chemosensitive C-fibers, which are activated by
mechanical and chemical stimuli (21, 22). Activation of these
vagal sensory afferents leads to central reflexes including cough.
It has been demonstrated that stimulating TRPA1 channels
activates vagal bronchopulmonary C-fibers in the guinea pig
and rodent lung (23–25).
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
TRPA1 ligands are known to activate airway sensory
nerves. However, there is little knowledge concerning the
functional effects of these agents. No data currently exist
profiling these ligands in clinical studies in the lung.
What This Study Adds to the Field
TRPA1 ligands evoked reproducible tussive responses in
an animal model and in humans.
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The aim of these experiments was to employ a series of
preclinical and clinical studies to determine, for the first time,
whether activation of the TRPA1 channel can evoke a tussive
response. Evidence to this effect could result in a deeper
understanding of the pathogenesis of cough and lead to the
development of novel treatment modalities.
METHODS
Functional Characterization of Cloned TRPA1 Expressed
in HEK293 Cells
TRPA1-expressing HEK293 cells and the method used to measure
increases in intracellular calcium levels in this study have been
described previously (26; and see the online supplement).
Animals
Male Dunkin-Hartley guinea pigs (300–500 g) were housed in a tem-
perature-controlled (218C) room with food and water freely available
for at least 1 week before commencing the experiment. The experi-
ments were performed in accordance with the U.K. Home Office
guidelines for animal welfare based on the Animals (Scientific Pro-
cedures) Act of 1986.
Effect of TRPA1 Ligands on Isolated Vagal Nerve Preparation
To demonstrate a functional response of TRPA1 channel activation in
native tissue we used our fully characterized isolated vagal nerve
preparation as described in previous publications (27, 28). Sensory
nerve responses to the two TRPA1 agonists, acrolein and cinnamalde-
hyde, were determined. For these experiments only one response to
one agonist was obtained in each segment of vagus. We also performed
experiments with the selective TRPA1 inhibitor, HC-030031, or vehicle
(dimethyl sulfoxide, 0.1% [vol/vol]) (17). To demonstrate antagonist
selectivity HC-030031 was also tested against the TRPV1 agonist
capsaicin, using a parallel protocol. To provide additional proof-of-
concept data an alternative antagonist was also used, AP-18 (29).
To further confirm that the response observed was via activation of
the TRPA1 channel we performed parallel agonist (acrolein) experi-
ments using vagal tissue from wild-type and Trpa12/2 gene-deleted
mice (Jackson Laboratory, Bar Harbor, ME). We confirmed the
deletion of the Trpa12/2 gene in the knockout mice, and not the wild
type, using standard genotyping techniques.
Effect of TRPA1 Ligand Acrolein in Guinea Pig Conscious
Cough Model
Cough was detected both by pressure change and by sound and
recorded with a Buxco cough analyzer (Buxco, Wilmington, NC) as
previously described (28). Guinea pigs received an aerosol of vehicle
(0.9% sterile saline, n5 12) or acrolein (10, 30, 100, or 300 mM, n5 12,
concentration derived from a preliminary study) for 5 minutes and
coughs were counted during this period and for a further 5 minutes
with the Buxco cough analyzer.
Having established a submaximal dose of acrolein, we confirmed
the role of TRPA1 using the selective inhibitor HC-030031. Guinea
pigs were dosed with vehicle (0.5% methyl cellulose in sterile saline
at 1 ml/kg, administered intraperitoneally, n 5 12) or HC-030031
(300 mg/kg, dose selected from data published by McNamara and
colleagues [17]). One hour later the guinea pigs were exposed to
a submaximal dose of TRPA1 agonist and cough was monitored as
outlined previously.
In Vitro Functional Characterization of TRPA1 in Isolated
Human Vagal Tissue
Briefly, human trachea, with branches of the cervical vagus still
attached, was obtained from three unused donor tissue samples surplus
to clinical requirement (two males, 32–55 yr of age) collected for heart–
lung transplantation. Relevant approvals were obtained from the next
of kin and the Royal Brompton and Harefield Trust Ethics Committee.
The isolated human vagus was exposed to a TRPA1 agonist and
antagonist as described previously for the guinea pig experiments.
Characterization of Tussive Response to Inhalation of TRPA1
Agonist in Human Volunteers
Healthy male and female, nonsmoking volunteers with normal lung
function were entered into a randomized, crossover study of inhala-
tional cough challenge of three tussive agents. Informed written
consent was obtained from all the volunteers and the study was
approved by the Hull and East Yorkshire Ethics Committee. Volun-
teers were randomized to inhalational cough challenge with the
TRPA1 agonist diluent or cinnamaldehyde or capsaicin or citric acid.
At Visit 1 a baseline cough challenge was performed and repeated
1 hour later with the same agent. The subjects were asked to return on
two occasions 2–3 days apart when the protocol was repeated with an
alternative cough stimulus. Each subject was recalled 2–3 days later for
Visit 4 when a subthreshold dose (i.e., the dose below that evoking
cough) of cinnamaldehyde or diluent was administered followed by
a repeat cough challenge to capsaicin and citric acid, which was
performed 1 hour later. This was repeated 2–3 days later at Visit 5 with
the alternative subthreshold inhalation. Safety assessments were per-
formed at all these visits.
Nebulizations were performed with a MEFAR MB3 dosimeter
(Mefar Elletromedicale, Bovezzo, Italy) with a Respironics nebulizer
chamber and mouthpiece according to our previously described
methodology (30). The dosimeter was set to nebulize for 1 second
and 2 ml of the agent was instilled into the nebulizer chamber. Coughs
induced were assessed during the subsequent 15 seconds after the
nebulization. Serial dilutions from stock (1 M citric acid, 1 mM
capsaicin) were made with 0.9% saline whereas 50% ethanol was used
as the diluent for cinnamaldehyde (800 mM).
Compounds and Materials
Fluo-3 acetoxymethyl ester and LipofectAMINE 2000 were purchased
from Invitrogen (Paisley, UK). Penicillin–streptomycin, fetal calf
serum, Dulbecco’s modified Eagle’s medium, sodium pyruvate, and
geneticin (G418) were all bought from GIBCO (Paisley, UK). The
TRPA1 inhibitor HC-030031 was purchased from ChemBridge (San
Diego, CA). All other agents were purchased from Sigma-Aldrich
(Poole, Dorset, UK). All other details are in the online supplement.
Data Analysis and Statistics
Antagonism of TRPA1 agonists was analyzed by two-tailed paired
t test, comparing responses to agonist (in the same piece of vagus
nerve) in the absence and presence of antagonist. Responses to TRPA1
ligands in gene-deleted mice were analyzed by Kruskal-Wallis test
for multiple comparisons with Dunn’s post-hoc test, comparing the
responses in each TRPA1 receptor knockout with those of the wild-
type control. Inhibition of acrolein-induced cough was analyzed by
Mann-Whitney U test for nonparametric data. Data are presented as
means 6 SEM and statistical significance is denoted as *P , 0.05.
In the clinical study end points were taken as the concentration at
which two or more coughs were induced (C2) and at which five or more
coughs were induced (C5). For the purposes of statistical analysis the
data were log transformed. SPSS version 13.0 was used for statistical
analysis. Paired t tests or Wilcoxon analysis was performed when appli-
cable. A P value of 0.05 or less was considered statistically significant.
RESULTS
In Vitro Functional Characterization of TRPA1 Ligands on
Cloned Human TRPA1 Channels in HEK293 Cells
The TRPA1 receptor was successfully cloned from primary
human fibroblasts and permanently expressed in HEK293 cells.
Reverse transcription-polymerase chain reaction showed that
HEK293 cells do not endogenously express TRPA1 mRNA (see
Figure E1 in the online supplement).
Calcium signaling was used to assess agonist-induced activa-
tion of TRPA1-HEK cells (Figure 1). hTRPA1-HEK cells
responded to both cinnamaldehyde and acrolein in a concentra-
tion-dependent manner (Figure 1). None of the agonists tested
stimulated an observable increase in calcium in nontransfected
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or mock-transfected HEK cells or in hTRPV1-HEK cells
(Figure 1). These results also demonstrated that HC-030031
caused inhibition of both cinnamaldehyde- and acrolein-evoked
responses in a concentration-dependent manner.
Effect of TRPA1 Ligands on Isolated Guinea Pig Vagal
Nerve Preparation
Tussive agents such as capsaicin, low-pH solutions, and prosta-
glandin E2 (PGE2) are known vagal sensory nerve stimulants
and as such isolated guinea pig, murine, and human vagus nerve
preparations have been shown to elicit nerve depolarization
responses to these stimulants (27, 28, 31). Furthermore, these
agents are also known tussigenic agents in human and animal
studies (5, 6, 32). These data suggest that the isolated vagus
nerve is a useful and predictive preparation for conducting
comprehensive pharmacological assessments of agents that may
activate or inhibit sensory nerve function and thus the cough
reflex. Previous data also suggest that the information generated
is broadly predictive of data generated in single afferent nerve
fiber recording studies, further validating the use of the isolated
vagus preparation.
Therefore, to demonstrate a functional role for the TRPA1
channel in a native tissue, we demonstrated a concentration-
related increase in the depolarization of the guinea pig isolated
vagus (indicative of sensory nerve activation) with acrolein
(Figure 2A). Furthermore, data obtained with cinnamaldehyde
produced a similar pattern (see Figure E2 in the online
supplement). To further confirm a role for TRPA1, we demon-
strated that the selective TRPA1 inhibitors AP-18 and HC-
030031 blocked depolarization in response to acrolein (Figures
2B and 2C). However, HC-030031 did not affect responses
evoked by capsaicin (Figure 2C). In addition, we have shown
that the vagus from Trpa12/2 mice failed to respond to the
TRPA1 agonist acrolein, but depolarized in response to a TRPV1
agonist, capsaicin. The wild-type preparations responded appro-
priately to these stimuli (Figure 2D).
Effect of TRPA1 Ligand Acrolein in a Conscious Guinea
Pig Cough Model
To demonstrate that the observations in the isolated tissue
translate in vivo we exposed guinea pigs to aerosolized acrolein.
As can be seen in Figure 3, the TRPA1 agonist caused a dose-
Figure 1. Calcium signaling was used to assess agonist
induced activation of TRPA1-HEK cells and agonist-induced
activation of TRPA1-HEK cells after preincubation with the
antagonistHC-030031. (A)Cinnamaldehydeconcentration–
response curve (squares) in hTRPA1-HEK cells. hTRPV1-HEK
cells failed to respond to 100 mM cinnamaldehyde (tri-
angle). (B) Acrolein concentration–response curve (squares)
in hTRPA1-HEK cells. hTRPV1-HEK cells failed to respond
to 300 mM acrolein (triangle). (C ) Effect of increasing
HC-030031 concentrations on cinnamaldehyde (30 mM)-
evoked calcium responses. (D) Effect of increasing HC-
030031 concentrations on acrolein (3 mM)-evoked calcium
responses. Results are expressed as means 6 SEM of up to
seven experiments, each performed in duplicate. *Statistical
significance (P , 0.05) from vehicle-treated group.
Figure 2. (A) Characterization of the depolarization
(mV) responses elicited by isolated guinea pig vagus
nerve preparations in response to the TRPA1 agonist
acrolein. (B and C ) Effect of TRPA1 channel blockers
(AP-18, 1–10 mM; and HC-030031, 0.3–30 mM) on
acrolein (300 mM)- or capsaicin (1 mM)-induced
depolarization of isolated guinea pig vagus nerve
preparations. Values are presented as means 6 SEM
of the percentage inhibition of depolarization before
and after drug superfusion (n 5 4). (D) Depolariza-
tion (mV) in response to TRPA1 (acrolein, 1 mM)/
TRPV1 (capsaicin, 1 mM) agonists in vagal nerve
tissue from wild-type and Trpa12/2 gene-deleted
mice. Results are expressed as the mean 6 SEM of
four to six experiments. KO, knockout.
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related increase in coughs. To confirm that the response was
through the TRPA1 channel we performed experiments in
which the guinea pigs were pretreated with the TRPA1 in-
hibitor before exposure to acrolein. In these experiments HC-
030031 significantly inhibited the tussive response to acrolein
(Figure 3).
In Vitro Functional Characterization of Response to TRPA1 in
Isolated Human Vagal Tissue
To demonstrate that the observations in guinea pigs and mice
translated to humans we paralleled the key vagal experiments
with tissue collected from donor lung samples. Figure 4 shows
that the human vagus is activated by acrolein (Figure 4A) and
that this response is inhibited by a TRPA1 antagonist (Figure
4B).
Demonstration of Tussive Response to TRPA1 Agonist in
Human Volunteers
Ten subjects (6 males; mean age, 33.5 yr) were studied. In-
halation of nebulized cinnamaldehyde (but not diluent) induced
cough in all subjects. One subject did not achieve C5 (the
concentration inducing five or more coughs) at the highest
concentration. One subject became nauseous at C2 (the con-
centration causing two or more coughs) and was withdrawn
from further study. There was a distinct concentration–response
relationship to inhaled cinnamaldehyde (Figure 4C). The me-
dian C2 for the baseline cinnamaldehyde challenge was 200 mM
(range, 125–not achieved) with no significant tachyphylaxis seen
with the second challenge (median C2, 275 mM [range 125–
800]). The median C5 was 312.5 mM (range, 125–not achieved)
compared with 387.5 mM (range, 125–not achieved) at 1 hour
from baseline. These values are compared with citric acid and
capsaicin challenge in the same subject in Table 1. Citric acid
was the only agent that showed significant tachyphylaxis (P 5
0.02) for C5. The prior inhalation of a subthreshold dose of
cinnamaldehyde or of the diluent did not have any effect on
subsequent cough challenge. Inhalation of cinnamaldehyde was
well tolerated with no adverse effects other than mild nausea in
one person.
DISCUSSION
Inhalational exposure to numerous irritating gases, fumes,
dusts, vapors, chemicals, and endogenous mediators can lead
to the development of cough. It has long been established that
TRPV1 receptor activation can elicit a cough response in both
animal models and in humans (5–7). This receptor is polyvalent,
and is activated by vanilloids (e.g., capsaicin), noxious heat
(>428C), extracellular protons (pH < 5.9), and endogenous
lipids (e.g., anandamide) and eicosanoids [e.g., leukotriene B4,
12-(S)-hydroperoxyeicosatetraenoic acid, and 15-(S)-hydroper-
oxyeicosatetraenoic acid]. However, it does not respond to many
irritants known to initiate cough. The mechanism whereby a
range of seemingly diverse irritants initiate acute and chronic
cough has remained a mystery. These data have identified, for
the first time, an alternative target for antitussive therapies that
responds to known environmental irritants.
We began by cloning human TRPA1 and permanently
expressing it in HEK293 cells and demonstrated that the reported
TRPA1 agonists activated this channel, confirming previous
data (19, 24). In house we have extensively characterized robust
and clinically relevant preclinical systems in which to test
potential sensory nerve modulators (27, 28). As the guinea pig
is the only small animal that possesses a cough reflex that
resembles the human response we used the isolated guinea pig
vagus in conjunction with an in vivo conscious guinea pig cough
model (28). Using the isolated guinea pig vagus preparation we
demonstrated that two different TRPA1 agonists were able to
Figure 3. (A) Dose response to inhaled acrolein in
conscious male guinea pigs (n 5 12). (B) Blockade of
the tussive response to acrolein with the TRPA1 ion
channel blocker HC-030031 (300 mg/kg). Guinea
pigs were dosed with vehicle or HC-030031 one hour
before the tussive challenge (n 5 12). Statistical
significance was determined by Mann-Whitney U
test for nonparametric data. Data are presented as
means 6 SEM and statistical significance is denoted
as *P , 0.05.
Figure 4. (A) Characterization of depolarization
(mV) responses elicited by isolated human vagus
nerve preparations in response to the TRPA1 agonist
acrolein. Results are expressed as means 6 SEM of
three experiments. (B) A representative trace de-
scribing depolarization of isolated human vagus
evoked by acrolein (1 mM) and inhibition in the
presence of the TRPA1 antagonist AP-18 (10 mM).
The response to acrolein is recovered after washout.
(C) Concentration–response curve of cinnamalde-
hyde inhaled at baseline and repeated 1 hour later
in human volunteers. Nebulizations were performed
with the MEFAR MB3 dosimeter with a Respironics
nebulizer chamber and mouthpiece. The dosimeter
was set to nebulize for 1 second and 2 ml of the
agent was instilled into the nebulizer chamber.
Coughs induced were assessed during the subse-
quent 15 seconds after the nebulization.
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activate sensory nerves and that this response could be attenu-
ated with selective TRPA1 inhibitors. Similar data demonstrating
inhibition of the TRPA1 channel with these inhibitors have been
generated by other investigators (17–19, 29). To strengthen this
pharmacological proof of concept we performed experiments
with knockout mice. We demonstrated that TRPA1 and TRPV1
agonists both activate vagal sensory nerves in the wild-type mice;
but that depolarization was achieved only by the TRPV1 agonist
capsaicin, on the isolated vagal preparations from mice from
which the Trpa1 gene was deleted. Although the vagus is a useful
and predictive preparation to use for a comprehensive pharma-
cological assessment of the activity of TRPA1 ligands on vagal
sensory nerve activation the data should be viewed with some
caution because pharmacological agents are applied to the axon
of the isolated vagus nerve in vitro and not the nerve ending. The
advantages and limitations of this preparation have been dis-
cussed at length in our previous publications (27, 28) however,
evidence to date suggests that the isolated vagus preparation is
predictive of data generated with single-fiber electrophysiological
preparations and data generated in the conscious guinea pig
cough mode (33). Furthermore, it is consistent with electrophys-
iological evidence suggesting that functional TRPA1 channels
exist in respiratory nociceptive sensory neurons and their termi-
nals (24). Next, we were able to show a dose–response relation-
ship between increasing challenges with a TRPA1 agonist and
the number of coughs in a guinea pig model. What is more, we
were able to attenuate this tussive response with a selective
TRPA1 inhibitor. To demonstrate that the preclinical data
generated in animal in vitro and in vivo models actually trans-
lated to humans, we paralleled the previous experiments, using
human vagal tissue.
With proof-of-concept data in an animal in vivo model and in
human tissue in vitro we were able to move on with confidence
to study normal human volunteers. The data from this study
clearly show that a TRPA1 agonist causes a concentration-
dependent cough in humans. The human cough response
appears to be reproducible and without significant tachyphylaxis
in this small data set. Agonizing TRPA1, using this protocol,
does not appear to impact on cough responses to other tussive
agents, suggesting a direct and specific response.
The TRPA1 receptor is activated by a number of irritant
chemicals including mustard oil (i.e., isothiocyanate), acrolein,
garlic, formalin, allicin, wasabi, cinnamon oil, diallyl disulfide,
allyl isothiocyanate, 4-hydroxynonenal, and 4-oxononenal (12–14,
16–18, 20, 23, 25). The mechanism of action would appear to be
through covalent modification of cysteine residues within the
cytosolic N terminus of TRPA1 by reactive electrophilic mole-
cules (16). This mode of action could be significant in patholog-
ical situations given that oxidant stress induced by either an
inflammatory response or by exogenous irritants, such as ciga-
rette smoke, can generate reactive electrophilic molecules in-
cluding acrolein and 4-hydroxynonenal. This also suggests that
the TRPA1 receptor is a promiscuous receptor that can be
activated by a wide range of stimuli, thus making it a perfect
target for triggering protective cough reflexes. However, more
work will be required to determine which of these putative
agonists are sufficiently potent to stimulate cough in vivo.
Interestingly, inflammation can lead to the formation of
endogenous electrophilic compounds in vivo (34). Examples
of such compounds are the cyclopentenone ring-containing A
and J series prostaglandins, which are formed as nonenzymatic
dehydration products of PGE2 and PGD2, respectively. Prosta-
noids that contain one or two electrophilic carbons such as
15PGJ2, D12-PGJ2, 8-iso-PGA2, and PGA2 are therefore able to
activate nociceptive neurons via direct interaction with TRPA1
(25). Furthermore, prostaglandins such as PGE2 and the in-
ducible form of cyclooxygenase-2 are elevated in respiratory
disease states at the site of inflammation (35–37). Taken to-
gether, this information would suggest that reactive prostanoids
and other endogenous TRPA1 ligands, which are produced in
greater amounts during inflammation or oxidant stress, could
evoke the cough seen in conditions such as asthma and chronic
obstructive pulmonary disease.
It is still unclear whether there is cooperation between
TRPV1 and TRPA1 channels. Both are activated by tussive
agents and so it could be possible that these TRP channels act
in concert to elicit functional responses. The dependence of
TRPA1 on Ca21 may result in the activation of TRPA1 chan-
nels by an overflow of Ca21 in the locale of other activated
channels without ever being modified by a reactive ligand. Fur-
thermore, TRPA1 channels may also act as an amplifier of other
Ca21-mobilizing pathways, including activation of TRPV1 (38).
However, whether this sort of cooperation exists in generating
a cough reflex has yet to be determined.
In conclusion, we have shown for the first time that acti-
vation of the TRPA1 channel can evoke a tussive response in
humans. This novel and exciting finding could have major
implications for understanding the pathogenesis of respiratory
diseases and for the treatment of cough, which presents as
a significant unmet medical need. Because of their central role
and activation by a wide range of irritant and chemical sub-
stances, either by exogenous agents, endogenously produced
mediators during inflammation, or by oxidant stress, we suggest
TRPA1 channels should be considered as one of the most
promising targets currently identified for the development of
novel antitussive drugs.
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